Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the time to progression in women with hormone responsive advanced breast cancer treated with combination of exemestane and fulvestrant.
Every 2 cycles
Ewa Mrozek, MD
Ohio State University
United States: Institutional Review Board
|Ohio State University||Columbus, Ohio 43210|